Size : | Price | Quantity | |
---|---|---|---|
10 mg | $60.00 | ||
50 mg | $195.00 |
Linsitinib (867160-71-2) is a potent and selective dual inhibitor of insulin-like growth factor 1 (IGF-1R) kinase and insulin receptor (InsR) kinase (IC50’s = 35 and 75 nM respectively).1 It has been investigated as a chemotherapeutic in combination with other drugs for various cancers.2-6
References/Citations:
1) Mulvihill et al. (2009), Discovery of OSI-906: a selective and orally efficacious inhibitor of the IGF-1 receptor and insulin receptor; Future Med. Chem. 1 1153
2) Bendell et al. (2015), A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer; Invest. New Drugs 33 187
3) Pivonello et al. (2016), The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma ; Oncotarget 7 9718
4) Lee et al. (2016), Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells; Mol. Carcinog. 55 991
5) Macaulay et al. (2016), Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors; Clin. Cancer Res. 22 2897
6) De Lint et al. (2016), Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R; Mol. Cancer Ther. 15 1545
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Linsitinib (867160-71-2) is a potent and selective dual inhibitor of insulin-like growth factor 1 (IGF-1R) kinase and insulin receptor (InsR) kinase (IC50’s = 35 and 75 nM respectively).1 It has been investigated as a chemotherapeutic in combination with other drugs for various cancers.2-6
References/Citations:
1) Mulvihill et al. (2009), Discovery of OSI-906: a selective and orally efficacious inhibitor of the IGF-1 receptor and insulin receptor; Future Med. Chem. 1 1153
2) Bendell et al. (2015), A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer; Invest. New Drugs 33 187
3) Pivonello et al. (2016), The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma ; Oncotarget 7 9718
4) Lee et al. (2016), Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells; Mol. Carcinog. 55 991
5) Macaulay et al. (2016), Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors; Clin. Cancer Res. 22 2897
6) De Lint et al. (2016), Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R; Mol. Cancer Ther. 15 1545
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.